Associate Director, Scientific Communications

Who We Are

Xenon Pharmaceuticals (NASDAQ:

XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Building upon the positive results and compelling data from our Phase 2b X-TOLE study in adult patients with focal epilepsy, our Phase 3 epilepsy program includes multiple clinical trials evaluating azetukalner in patients with focal onset seizures and primary generalized tonic‑clonic seizures.

In November 2025, we announced the completion of patient enrollment in our Phase 3 X-TOLE2 study, and topline data are anticipated in March 2026. We also have multiple Phase 3 azetukalner clinical trials in major depressive disorder (MDD) and bipolar depression (BPD) underway, based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of the leading‑edge science coming out of our discovery labs, including early‑stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates.

We have recently initiated Phase 1 studies for our follow‑on Kv7 channel opener, XEN
1120, and our lead Nav
1.7 development candidate, XEN
1701, in pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

We are seeking a Associate Director, Scientific Communications to support the development and execution of field medical and congress materials for our epilepsy and neuropsychiatry programs, while contributing to broader Medical Affairs priorities across the Xenon pipeline. This role plays a central part in shaping scientifically rigorous, compliant, and strategically aligned materials that engage and educate health care professionals. The Associate Director, Scientific Communications will support the development, review, and approval of scientific content, ensuring alignment with key Medical Affairs and cross‑functional platforms, strategic objectives, and tactical plans.

Success in this role requires a strong scientific foundation paired with the ability to distill complex neuroscience into scientifically accurate, clear, and compelling narratives tailored for diverse audiences. In addition, you must be a highly collaborative scientific or clinical professional who thrives in a dynamic, fast‑paced environment and is committed to operational excellence.

This position reports to the Director of Scientific Communications and operates within a multidisciplinary team, interfacing with cross‑functional internal stakeholders and external experts. Your contributions will directly shape how Xenon communicates scientific insights, supports strategic initiatives, and advances its programs in epilepsy and neuropsychiatric disorders. This role will be based out of Boston, MA, USA in our Needham office. Hybrid positions require a minimum of two onsite days per week.

On‑site positions require up to five on‑site days per week.

• Support the development of field medical materials and congress deliverables aligned to epilepsy and neuropsychiatry program needs.

• Translate complex data into clear, compelling narratives tailored to internal and external audiences.

• Partner closely with Medical Affairs, Commercial, Clinical Development, Regulatory, and other cross‑functional stakeholders to develop materials that are scientifically rigorous, compliant, and consistent with scientific communications platforms, lexicons, therapeutic‑area strategy, evidence generation plans,…